These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 21159709

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [Abstract] [Full Text] [Related]

  • 5. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C, Jeske WP, Hoppensteadt D, Walenga JM, Bansal V, Fareed J.
    Clin Appl Thromb Hemost; 2009 Jul; 15(2):137-44. PubMed ID: 19357102
    [Abstract] [Full Text] [Related]

  • 6. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [Abstract] [Full Text] [Related]

  • 7. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
    Kaffenberger BH, Bekaii-Saab T.
    Clin Appl Thromb Hemost; 2012 Feb; 18(1):104-6. PubMed ID: 21873360
    [Abstract] [Full Text] [Related]

  • 8. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
    Ofosu FA.
    Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM, Jackson CM, Kessler CM.
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM, Jeske WP, Hoppensteadt D, Cunanan J, Khan H, Escalante V, Fareed J, Bakhos M.
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [Abstract] [Full Text] [Related]

  • 14. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC.
    J Clin Psychiatry; 2001 Jun; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [Abstract] [Full Text] [Related]

  • 15. FDA approves generic enoxaparin.
    Voelker R.
    JAMA; 2010 Aug 25; 304(8):844. PubMed ID: 20736461
    [No Abstract] [Full Text] [Related]

  • 16. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ.
    Drugs; 2015 Apr 25; 75(6):633-50. PubMed ID: 25822610
    [Abstract] [Full Text] [Related]

  • 17. Scientific considerations in the regulatory approval of generic (or biosimilar) version of enoxaparin sodium - A lifesaving carbohydrate polymer.
    Iqbal Z, Sadaf S.
    Regul Toxicol Pharmacol; 2023 Sep 25; 143():105446. PubMed ID: 37532121
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2010 Jan 25; 48(1):13-6. PubMed ID: 20102127
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.